February 14, 2014—Lumenis (Yokneam, Israel), maker of medical lasers for minimally-invasive clinical solutions, announced yesterday the launch of an initial public offering of 6,250,000 ordinary B shares in accordance with a registration statement filed with the U.S. Securities and Exchange Commission. A further 937,500 additional ordinary B shares were on offer as a 30-day option to underwriters. The price range for the shares is between $15 and $17 per share, and is expected to raise between $100 million and $122.2 million. The midpoint of the expected range would place the company at a fully diluted market value of $597 million.
The flotation date has not yet been specified, but the company plans to list on the NASDAQ under the symbol LMNS.
Goldman, Sachs & Co; Credit Suisse Securities LLC and Jeffries LLC will serve as co-book-running managers for the offering, while Wells Fargo Securities LLC will serve as co-manager. The offering will be made available only via prospectus.
Lumenis, self-billed as “the world’s largest and most diversified medical laser company,” formed in 1991, reportedly booked $265 million in sales for the year ending December 31, 2013, a growth of 6.7 percent over the prior year. The company’s net income of $17.4 million for 2013 is a growth of 148.6 percent year-over-year.
The company’s market segments are comprised of three areas: surgical, ophthalmic and aesthetic. In the surgical realm, the company pioneered the development of high-powered holmium lasers for urology. Lumenis’ CO2 laser systems are used in the treatment of benign and malignant lesions, as well as inflammations in the ear, nose and throat (ENT) market.
In the ophthalmic segment, Lumenis introduced the first argon laser photocoagulator to ophthalmologists in 1970. They were also the first approved marketer of Nd:YAG photodisruptor lasers.
In the aesthetic realm, Lumenis pioneered the introduction of intense pulsed light and CO2 laser skin resurfacing.